OncoMed’s bad, no good, disastrous month continues as another PhII flops, PhIb trial is shuttered
A few days ago, shares of OncoMed $OMED were blitzed by the news that its top drug demcizumab had flopped in a Phase II study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
